Zurich Insurance Group Ltd, one of Europe's largest insurers, has executed a landmark capital raise to support its ambitious acquisition of Beazley plc, a prominent London-listed specialist insurer.

Details of the Capital Raise

The Swiss-based group completed the placement of 7,090,909 new registered shares at CHF 550 each, generating gross proceeds of approximately CHF 3.9 billion. This accelerated bookbuilding process ensures swift funding for the deal, with net proceeds earmarked to partially finance the purchase. The remaining portion will be covered by Zurich's existing cash reserves and new debt facilities.

The new shares, each with a par value of CHF 0.10, will increase Zurich's share capital from CHF 14.6 million to CHF 15.3 million. They rank equally with existing shares and qualify for the CHF 30 per share dividend for fiscal year 2025. Listing and trading on the SIX Swiss Exchange are anticipated around March 5, 2026, with settlement to follow shortly after.

Acquisition Terms and Strategic Rationale

Under the terms announced on March 2 in line with the UK Takeover Code, Beazley shareholders stand to receive 1,335 pence per share. This comprises 1,310 pence in cash plus a 25 pence interim dividend for the year ended December 31, 2025, payable around May 1, 2026.

Beazley, known for its expertise in specialty lines such as political risk and contingency insurance, represents a strategic bolt-on for Zurich. The acquisition enhances Zurich's footprint in the Lloyd's of London market and bolsters its non-life insurance portfolio, aligning with broader industry trends towards scale amid rising geopolitical and cyber risks.

Market Context and Implications

This deal arrives against a backdrop of moderating UK inflation pressures, with shop price inflation dipping to 1.1% in February, offering some relief ahead of the spring statement. For the insurance sector, it signals confidence in sustained premium growth and investment returns.

Zurich has also committed to a 90-day lock-up period, restricting further share issuances to stabilise the stock post-placement. Investors will watch closely as the transaction progresses, potentially reshaping competitive dynamics in the UK and global specialty insurance landscape.